Polivy®

Active substance

Polatuzumab vedotin

Holder

Roche

Status

Running

Indication

In combination with bendamustine and rituximab for relapsed or refractory adult patients with diffuse large B-cell lymphoma (DLBCL) who are not candidates for hematopoietic stem cell transplant and have been treated with at least two prior lines of therapy.

Public documents

Approbation

Information for the patient

Informed consent

Last update

01/09/2020

Last updated on 13/02/2024